Cefpodoxime Proxetil

MOA

Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.

Drug Label Information | Brands:

Brands of Cefpodoxime Proxetil available

Auropodox®, Aurobindo
Cacef ,galaxy Pharmaceutical Limited
Cefpodox®, Unicorn
Cefpowel DT , Unosource Pharma Limited
Cefoprox, Cipla Ltd
Cefwar®, Leben Laboratories Pvt Ltd
Cepodem®, Ranbaxy
Cepotil®, Orchid
Orelox®, Sanofi-aventis Kenya
Oxipod®, Indoco Remedies Limited
Vanprox®, Square
Cepom®, Questa
Cefaz®, Zest pharma
Dapodox®, Dawa
Cepom-200®,Stallion
Monocef-O, Aristo Pharmaceuticals Pvt.ltd
Poxil®, Bharat
Swich®, Alkem Laboratories
Tambac®, Cadila
Virdox, Virchow Healthcare Pvt Ltd
Ximeprox®, Incepta

INDICATIONS

Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.

Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.
100 mg Q 12 hours 5 to 10 days

NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available.

Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains).
200 mg Q 12 hours 14 days

Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae.

Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
200 mg single dose

Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N. gonorrhoeae in men or women.

Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes. Abscesses should be surgically drained as clinically indicated.

NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications.

Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis.

Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus.

NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents.

CONTRAINDICATIONS:

Cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics.

ADVERSE DRUG REACTIONS:

Diarrhea
Nausea
Vaginal Fungal Infections
Vulvovaginal Infections
Abdominal Pain
Headache
Adverse events less than 1%
Body – fungal infections, abdominal distention, malaise, fatigue, asthenia, fever, chest pain, back pain, chills, generalized pain, abnormal microbiological tests, moniliasis, abscess, allergic reaction, facial edema, bacterial infections, parasitic infections, localized edema, localized pain.

Cardiovascular – congestive heart failure, migraine, palpitations, vasodilation, hematoma, hypertension, hypotension.

Digestive – vomiting, dyspepsia, dry mouth, flatulence, decreased appetite, constipation, oral moniliasis, anorexia, eructation, gastritis, mouth ulcers, gastrointestinal disorders, rectal disorders, tongue disorders, tooth disorders, increased thirst, oral lesions, tenesmus, dry throat, toothache.

Hemic and Lymphatic – anemia.

Metabolic and Nutritional – dehydration, gout, peripheral edema, weight increase.

Musculo-skeletal – myalgia.

Nervous – dizziness, insomnia, somnolence, anxiety, shakiness, nervousness, cerebral infarction, change in dreams, impaired concentration, confusion, nightmares, paresthesia, vertigo.

Respiratory – asthma, cough, epistaxis, rhinitis, wheezing, bronchitis, dyspnea, pleural effusion, pneumonia, sinusitis.

Skin – urticaria, rash, pruritus non-application site, diaphoresis, maculopapular rash, fungal dermatitis, desquamation, dry skin non-application site, hair loss, vesiculobullous rash, sunburn.

Special Senses – taste alterations, eye irritation, taste loss, tinnitus.

Urogenital – hematuria, urinary tract infections, metrorrhagia, dysuria, urinary frequency, nocturia, penile infection, proteinuria, vaginal pain.


Prescription Category:
DDA Schedule:
Dosage Forms:
Routes of Administration:
Protein Binding:
Metabolosim:
Bioavailability:
Elimination Half life:
Drug Indentifiers:

References/ Citation:

Prescription Category:
DDA Schedule:
Dosage Forms:
Routes of Administration:
Protein Binding:
Metabolosim:
Bioavailability:
Elimination Half life:
Drug Indentifiers:

References/ Citation: